NC
INFI

Nexthera Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Nexthera Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-145,000
Closed -$764K – 41
2016
Q1 		$764K Buy
+145,000
New +$887K 0.79% 24

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital's INFI Position: Q2 2016 in Review

Nexthera Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2016, closing a stake of 145,000 shares — an estimated $764K sold.

Nexthera Capital first reported a position in INFI in Q1 2016 and held it in 1 quarter. The position peaked at $764K in Q1 2016. 107 funds tracked by Wall St. Rank hold INFI as of Q2 2016.

  • Nexthera Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Nexthera Capital sold 145,000 Infinity Pharmaceuticals, Inc. shares in Q2 2016, an estimated $764K.
  • Nexthera Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Nexthera Capital's Infinity Pharmaceuticals, Inc. position peaked at $764K in Q1 2016.
  • 107 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2016.

Based on Nexthera Capital's 13F filing for Q2 2016, filed 15 Aug 2016.